What is HC Wainwright's Forecast for TCRX FY2025 Earnings?

Key Points

• HC Wainwright has increased its FY2025 earnings per share estimate for TScan Therapeutics from ($1.18) to ($1.17), maintaining a "Buy" rating and a price target of $10.00.
• TScan Therapeutics reported a quarterly earnings per share of ($0.28), aligning with analysts' expectations, and achieved revenue of $3.08 million against estimates of $1.31 million.
• Institutional investors hold 82.83% of TScan Therapeutics' stock, indicating strong institutional interest in the company.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Research analysts at HC Wainwright raised their FY2025 earnings estimates for shares of TScan Therapeutics in a research report issued on Tuesday, August 12th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($1.17) per share for the year, up from their previous forecast of ($1.18). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics' FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.47) EPS and FY2029 earnings at $0.04 EPS.

A number of other research firms also recently weighed in on TCRX. Wall Street Zen raised shares of TScan Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. Wedbush reaffirmed an "outperform" rating and issued a $7.00 price target on shares of TScan Therapeutics in a research note on Tuesday, August 12th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $7.80.

TScan Therapeutics Stock Up 1.2%

NASDAQ:TCRX traded up $0.02 during trading hours on Friday, hitting $1.70. 160,216 shares of the stock traded hands, compared to its average volume of 465,197. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $6.2250. The company has a current ratio of 7.06, a quick ratio of 7.06 and a debt-to-equity ratio of 0.18. The firm has a market cap of $96.20 million, a price-to-earnings ratio of -1.56 and a beta of 0.99. The firm has a 50 day moving average price of $1.68 and a 200 day moving average price of $1.65.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. The company had revenue of $3.08 million for the quarter, compared to the consensus estimate of $1.31 million.

Institutional Investors Weigh In On TScan Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Lynx1 Capital Management LP boosted its holdings in TScan Therapeutics by 2.5% during the fourth quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock valued at $16,286,000 after acquiring an additional 132,747 shares during the period. BVF Inc. IL boosted its holdings in TScan Therapeutics by 6.9% during the second quarter. BVF Inc. IL now owns 5,226,074 shares of the company's stock valued at $7,578,000 after acquiring an additional 336,600 shares during the period. Checkpoint Capital L.P. boosted its holdings in TScan Therapeutics by 14.9% during the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company's stock valued at $2,784,000 after acquiring an additional 261,663 shares during the period. Aberdeen Group plc lifted its stake in shares of TScan Therapeutics by 0.9% in the first quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock valued at $1,230,000 after buying an additional 7,744 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in shares of TScan Therapeutics by 8.5% in the second quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company's stock valued at $417,000 after buying an additional 22,642 shares during the period. 82.83% of the stock is currently owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.